These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2790701)

  • 1. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer.
    Andersen J; Poulsen HS
    Cancer; 1989 Nov; 64(9):1901-8. PubMed ID: 2790701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment.
    Andersen J
    Acta Oncol; 1992; 31(6):611-27. PubMed ID: 1281648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response.
    Andersen J; Poulsen HS
    J Steroid Biochem; 1988; 30(1-6):337-9. PubMed ID: 3386262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical assay for estrogen receptor with monoclonal antibody D753P gamma in routinely processed formaldehyde-fixed breast tissue. Comparison with frozen section assay and with monoclonal antibody H222.
    Miller RT; Hapke MR; Greene GL
    Cancer; 1993 Jun; 71(11):3541-6. PubMed ID: 8490902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays.
    Andersen J; Thorpe SM; King WJ; Rose C; Christensen I; Rasmussen BB; Poulsen HS
    Eur J Cancer; 1990 Apr; 26(4):442-9. PubMed ID: 1694085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay.
    Andersen J; Thorpe SM; Rose C; Christensen I; Rasmussen BB; Poulsen HS
    Acta Oncol; 1991; 30(6):685-90. PubMed ID: 1958387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.
    Saccani Jotti G; Johnston SR; Salter J; Detre S; Dowsett M
    J Clin Pathol; 1994 Oct; 47(10):900-5. PubMed ID: 7962603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor.
    Damstrup L; Andersen J; Kufe DW; Hayes DF; Poulsen HS
    Ann Oncol; 1992 Jan; 3(1):71-7. PubMed ID: 1606073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays.
    Pertschuk LP; Feldman JG; Kim YD; Braithwaite L; Schneider F; Braverman AS; Axiotis C
    Cancer; 1996 Jun; 77(12):2514-9. PubMed ID: 8640700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.